Keros Therapeutics, Inc. KROS

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
72/100
Moderate

Ranked against 712 peers in Biotechnology

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in … Full KROS analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 87.7th percentile exceeds peers and WACC, demonstrating superior capital allocation.
  • Cost Leadership Position Operating margin at 92.8th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.07), suggesting weak customer stickiness.
  • Elevated Debt Risk Debt serviceability is weak (score 0.39), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
61
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where KROS ranks in Biotechnology

Keros Therapeutics, Inc. ranks #43 of 713 scored companies in Biotechnology by moat score — the top 6%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
39 Vaxart, Inc. - Common Stock VXRT 73/100 Moderate
40 CureVac N.V. CVAC 73/100 Moderate
41 MannKind Corporation MNKD 72/100 Moderate
42 Contineum Therapeutics, Inc. CTNM 72/100 Moderate
43 Keros Therapeutics, Inc. KROS 72/100 Moderate
44 Novavax, Inc. NVAX 71/100 Moderate
45 Soleno Therapeutics, Inc. SLNO 71/100 Moderate
46 CorMedix Inc. CRMD 70/100 Moderate
47 Theravance Biopharma, Inc. TBPH 70/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How KROS scores on the Corporate Default defenses

Pricing Power

Score 61 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 94 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 61 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 81 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 66 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 69 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding KROS's moat

What is Keros Therapeutics, Inc.'s moat score?

Keros Therapeutics, Inc. (KROS) scores 72 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #43 of 713 scored companies in Biotechnology, the top 6%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (94/100) and its weakest is Customer Stickiness (61/100).

How does Keros Therapeutics, Inc. compare with other Biotechnology companies?

Keros Therapeutics, Inc. ranks #43 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Contineum Therapeutics, Inc. (CTNM) at 72 just above it and Novavax, Inc. (NVAX) at 71 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Keros Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Keros Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and KROS scores: Pricing Power (61), Cost Advantage (94), Customer Stickiness (61), Capital Efficiency (81), Resilience (66), Scale & Market Position (69). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000